BioCardia was founded in 1999 to enable biointerventional cardiology and is
headquartered in South San Francisco, California.
BioCardia’s Helix Biotherapeutic Delivery business remains committed to
being the platform of choice for delivery of therapeutic agents to the
myocardium. Novel biotherapeutic approaches have enormous promise in
addressing unmet clinical needs in hundreds of thousands of patients
suffering from cardiovascular diseases each year. The Helix Biotherapeutic
Delivery platform is currently the enabling delivery system in use in
multiple ongoing clinical trials.
BioCardia’s Morph Access Innovations business is based on the advances
realized in steerable catheter shaft technology that were developed to
support the Helix biotherapeutic delivery business. BioCardia has a growing
family of FDA cleared Morph deflectable guide catheters that have been used
in more than 1000 clinical cases with a perfect safety record. The Morph
Access Innovations engineeri